CD44 is one of the most frequently observed cancer stem cell (CSC) markers in solid tumors, and it was revealed to be a target of the Wnt pathway[48], which is accepted as a main pathway for the stemness maintenance of CSCs, and usually accepted as a poor prognosis marker. The gene discussed is CD44; the disease is cancer.